NingDan New Drug (Nanjing NingDan New Drug Technology Co., Ltd.) is a biopharmaceutical company dedicated to discovery and development of multi-mechanism therapies for CNS diseases, supported by an in-house R&D platform and a specialized CNS clinical research team. The founding team has focused on CNS drug R&D for more than a decade and has built a portfolio of international, clinically advanced assets. Lead assets include Y-2 sublingual tablet (China marketing application submitted and accepted), Y-3 injection (completed global Phase II and poised to enter China Phase III), Y-1 injection (China Phase I/IIa), Y-6 sublingual tablet (China Phase II), and Y-4 tablet (FDA IND tacit acceptance). The company reports multiple preclinical/pre-IND pipeline programs with stage-specific progress. NingDan plans to use new capital to advance global development and international collaborations across its pipeline and to further its competitive position in major CNS markets. NeuroDawn (南京宁丹新药) is a biopharmaceutical company developing treatments for acute ischemic stroke, including a sublingual formulation and a novel injectable small molecule. Its lead partnered program is the Y-2 sublingual tablet (先必新舌下片), in a registrational Phase 3 study with Simcere Pharmaceutical, designed for rapid, out-of-hospital dosing. The company is also developing Y-3, a class‑1 small‑molecule PSD-95/nNOS uncoupling injectable with dual activity including α2‑GABAAR agonism aimed at reducing excitotoxic injury and improving post‑stroke emotional outcomes. NeuroDawn announced an oversubscribed A+ financing of over RMB100 million to accelerate clinical registration, R&D, platform development, and international collaborations. The financing and existing industry partnerships are intended to speed filing and commercialization of its core clinical programs. Ningdan Pharmaceutical is a developer of new drugs for central nervous system (CNS) disorders, with a focus on stroke and related neurological diseases. The company concentrates on introducing, developing and industrializing CNS innovative medicines. Its pipeline includes two Class‑1 new drugs in clinical phases (I and III), two Class‑1 candidates in preclinical research with IND submissions planned by year-end, and multiple additional candidates nearing preclinical development. Ningdan expects to file 3–4 INDs and have 2–3 products complete Phase I and enter Phase II by the end of 2022. The team comprises more than 70 staff; the core technical team has years of CNS drug R&D experience and has previously developed and launched one similar new drug. Financially, the company recently closed financing to support preclinical and clinical studies and to expand the team.

Total raised

$53M

Funding rounds

3

Latest round

Series B

Latest activity

Nov 2023